Novacyt S.A. ("Novacyt", the "Company" or the "Group")

R&D and UK Operational Update - Seite 3

Expansion of the SNPsig PCR genotyping portfolio

In addition to Novacyt’s recently launched CE-IVD assay panel, VariPLEX, the Company has eight RUO assays, which it believes is the most complete variant detection portfolio currently available to address the globally prevalent variants of SARS-CoV-2.

An RUO assay to detect a new variant originally identified in India is expected to be launched in the next week and reinforces Novacyt’s leadership in responding to an urgent public health need and market requirements. (Full detail on the SNPsig portfolio can be found below.)

UK operational update

Novacyt has invested significantly in supporting the UK market during the past 12 months and now has over 50 field specialists servicing the NHS across England, Wales, Scotland and Northern Ireland. In addition, Primerdesign and Microgen Bioproducts, Novacyt’s wholly owned subsidiaries, have been included in the National Microbiology Framework for Diagnostic Goods and Services (Lot 1) published by PHE for a full range of clinical products, including tests within the Company’s accredited portfolio.

The successful inclusion of Primerdesign and Microgen Bioproducts in the PHE National Framework Agreement, coupled with the Company’s investment in its commercial infrastructure to deliver new products and establish a direct sales force, means Novacyt is well positioned to develop a long-term commercial position in the UK market.

About the SNPsig portfolio

The table below contains details on Novacyt's SNPsig portfolio of products, which have been launched to date or are due to launch imminently. Novacyt's bioinformatics surveillance group remains highly vigilant and, as significant new mutations are identified, these will be added to the SNPsig portfolio.

Assay Type			Detection Profile
SNPsig VariPLEX SARS-CoV-2			20I/501Y.V1, 20H/501Y.V2, 20J/501Y.V3, 20C/S.452R, N501Y, E484K
SNPsig SARS-CoV-2 (20I/501Y.V1)			20I/501Y.V1 (UK)
SNPsig SARS-CoV-2 (20H/501Y.V2)			20H/501Y.V2 (SA)
SNPsig SARS-CoV-2 (20J/501Y.V3)			20J/501Y.V3 (Brazil)